Fig. 2: Local and systemic solicited adverse events.
From: Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
Related (a) local and (b) systemic solicited AEs documented within 56 days after CoVac-1 administration. Severity was graded as normal (grade 0), mild (grade 1), moderate (grade 2), or severe (grade 3) based on the definition provided in the methods section and the Supplementary Information.
